Evaluation of routine diabetes and lipid screening after age 35 in candidates for or current users of oral contraceptives

Obstetrics and Gynecology

Volumn 82, Issue 6, 1993, Pages 925-930

  Kjos, Siri L ^a   Gregory, Kimberly ^a   Henry, Olivia A ^a   Collins, Christine ^a  

^a LAC USC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; DIABETES MELLITUS; FEMALE; GLUCOSE TOLERANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIPID METABOLISM; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PRIORITY JOURNAL; SCREENING;

ADULT; BLOOD GLUCOSE; CHOLESTEROL; CONTRACEPTIVES, ORAL, HORMONAL; DIABETES MELLITUS; FEMALE; HUMAN; MASS SCREENING; PROGRAM EVALUATION; RISK FACTORS; TRIGLYCERIDES;

EID: 0027500723     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Ory HW. Mortality associated with fertility and fertility control. Fam Plann Perspect 1983;15:50-63.
2. Inman WHW, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptive. A report to the Committee on Safety of Drugs. Br Med J 1970;2:203-9.
3. Stadel BV. Oral contraceptives and cardiovascular disease (part 2). N Engl J Med 1981;305:672-7.
4. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
5. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.
6. Gordon DJ, Rifkind BM. High-density lipoprotein–the clinical implication of recent studies. N Engl J Med 1989;321:1311-6.
7. Beard CM, Kottke TE, Annergers JF, Ballard DJ. The Rochester Coronary Heart Disease Project: Effect of cigarette smoking, hypertension, diabetes and steroidal estrogen use on coronary heart disease among 40-to 59-year old women, 1960 through 1982. Mayo Clin Proc 1989;64:1471-80.
8. Crook D, Godsland BA, Wynn V. Oral contraceptives and coronary heart disease: Modulation of glucose tolerance and plasma lipid risk factors by progestins. Am J Obstet Gynecol 1988;158: 1612-20.
9. Perlman JA, Russel-Briefel R, Ezzati T, Lierberknect G. Oral glucose tolerance and the potency of contraceptive agents. J Chron Dis 1985;38:857-64.
10. Lipson A, Stoy DB, LaRosa JC, et al. Progestins and oral contraceptive-induced lipoprotein changes: A prospective study. Contraception 1986;34:121-34.
11. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990;323:1375-81.
12. Simon D, Senan C, Gamier P, et al. Effects of oral contraceptives on carbohydrate and lipid metabolisms in a healthy population: The Telecom Study. Am J Obstet Gynecol 1990;163:382-7.
13. van der Vange N, Kloosterboer HJ, Haspels AA. Effect of seven low-dose combined oral contraceptive preparations on carbohydrate metabolism. Am J Obstet Gynecol 1987;156:918-22.
14. Spellacy WN, Buhi WC, Birk SA. Carbohydrate metabolism prospectively studied in women using a low-estrogen oral contraceptive for six months. Contraception 1979;20:137-49.
15. Petersen KR, Skouby SO, Pederson RG. Desogestrel and gestodene in oral contraceptives: 12 months’ assessment of carbohydrate and lipoprotein metabolism. Obstet Gynecol 1991;78:666-72.
16. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
17. Metzger BE. Summary and recommendations of the Third International Workshop Conference on Gestational Diabetes. Diabetes 1991;40(suppl 2):197-201.
18. Friedwald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
19. Fahraeus L, Larsson-Cohn U, Wallentin L. Plasma lipoproteins including high-density lipoprotein subfractions during normal pregnancy. Obstet Gynecol 1985;66:468-72.
20. Kjos SL, Buchanan TA, Montoro M, et al. Serum lipids within thirty-six months of delivery in women with recent gestational diabetes mellitus. Diabetes 1991;140(suppl 2):142-6.
21. Kay CR. Progestogens and arterial disease–evidence from the Royal College of General Practitioners’ Study. Am J Obstet Gynecol 1982;142:762-5.
22. Mishell DR Jr. Medical progress: Contraception. N Engl J Med 1989;320:770-87.
23. Thorogood M, Vessey MP. Trends in use of oral contraceptives in Britain. Br J Fam Plann 1990;16:41-53.
24. Porter JB, Hunter JR, Jick H, Stergachis A. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 1985;66:1-4.
25. Porter JB, Jick H, Walker AM. Mortality among oral contraceptive users. Obstet Gynecol 1987;70:29-32.
26. Rosenberg L, Palmer JR, Lesko SM, Shapiro SM. Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol 1990;131:1009-16.
27. Spellacy WN, Buhi WC, Birk SA. The effect of estrogens on carbohydrate metabolism: Glucose insulin and growth hormone studies on one hundred seventy-one women ingesting Premarin, Mestranol and ethinyl estradiol for six months. Am J Obstet Gynecol 1972;114:378-92.
28. Wahl P, Walden C, Knopp R, et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. N Engl J Med 1983;308: 862-7.
29. Knopp RH, Walden CE, Wahl PW, Hoover JJ. Effects of oral contraceptives on lipoprotein triglyceride and cholesterol: Relationships to estrogen and progestin potency. Am J Obstet Gynecol 1982;142:725-31.
30. Krauss RM, Roy S, Mishell DR Jr, Casagrande J, Pike MC. Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: Differential changes in high-density lipoprotein subclasses. Am J Obstet Gynecol 1983;145:446-52.
31. Spellacy WN, Buhi WC, Birk SA. Carbohydrate and lipid metabolic studies before and after one year of treatment with ethyn-odiol diacetate in “normal” women. Fertil Steril 1976;27:900-4.
32. Kloosterboer HJ, van Wayjen RG, van den Ende A. Comparative effects of monophasic desogestrel plus ethinyl estradiol and triphasic levonorgestrel plus ethinyl estradiol on lipid metabolism. Contraception 1986;34:135-44.
33. Skouby SO, Kuhl C, Molsted-Pederson L, Petersen K, Christensen MS. Triphasic oral contraception: Metabolic effects in normal women and those with previous gestational diabetes. Am J Obstet Gynecol 1985;153:495-500.
34. Spellacy WN, Buhi MS, Birk SA. Effects of norethindrone on carbohydrate and lipid metabolism. Obstet Gynecol 1975;46: 560-3.
35. Harris MI, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma-glucose levels in U.S. population aged 20-74 yr. Diabetes 1987;36:523-34.
36. Stern MP, Gaskill SP, Hazuda HP, Gardner LI, Haffner SM. Does obesity explain the excess prevalence of diabetes among Mexican Americans? Results from the San Antonio Heart Study. Diabetologia 1983;24:272-7.
37. Kjos SL, Buchanan TA, Greenspoon JS, Montoro M, Bernstein GS, Mestman JH. Gestational diabetes mellitus; the prevalence of glucose intolerance and diabetes mellitus in the first two months postpartum. Am J Obstet Gynecol 1990;163:93-7.
38. Carrol M, Sempos C, Fulwood R, et al. Serum lipids and lipoproteins of Hispanics, 1982-84. National Center for Health Statistics, Public Health Service. Vital and health statistics 11(240). DHHS publication no. (PHS) 90-1690. Washington, DC: United States Government Printing Office, 1990.
39. Fulwood R, Kalsbeek W, Rifkind B, et al. Total serum cholesterol levels of adults 20-74 years of age: United States, 1976-1980. National Center for Health Statistics, Public Health Service. Vital and health statistics 11(236). DHHS publication no. (PHS) 86-1686. Washington, DC: United States Government Printing Office, May 1986.
40. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36-69.
41. American Diabetes Association position statement: Screening for diabetes. Diabetes Care 1989;12:588-90.